Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients

Marco Rastrelli, Beatrice Ferrazzi, Francesco Cavallin, Vanna Chiarion Sileni, Jacopo Pigozzo, Alessio Fabozzi, Saveria Tropea, Antonella Vecchiato, Alessandra Costa, Alessandro Parisi, Carlo Riccardo Rossi, Paolo Del Fiore, Mauro Alaibac

Research output: Contribution to journalArticle

Abstract

Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04⁻8.16) and disease-specific (HR 4.62, 95% CI 1.31⁻16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06⁻4.36) and recurrence-free (HR 3.08, 95% CI 1.44⁻6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.

Original languageEnglish
JournalCancers
Volume10
Issue number10
DOIs
Publication statusPublished - Sep 24 2018

Fingerprint

Merkel Cell Carcinoma
Survival
Recurrence
Neoplasms
Immunomodulation
Skin Neoplasms
Italy
Comorbidity
Patient Care
Cohort Studies
Therapeutics
Retrospective Studies
Databases

Cite this

Prognostic Factors in Merkel Cell Carcinoma : A Retrospective Single-Center Study in 90 Patients. / Rastrelli, Marco; Ferrazzi, Beatrice; Cavallin, Francesco; Chiarion Sileni, Vanna; Pigozzo, Jacopo; Fabozzi, Alessio; Tropea, Saveria; Vecchiato, Antonella; Costa, Alessandra; Parisi, Alessandro; Rossi, Carlo Riccardo; Del Fiore, Paolo; Alaibac, Mauro.

In: Cancers, Vol. 10, No. 10, 24.09.2018.

Research output: Contribution to journalArticle

@article{7834287bfcad402f8dc832d8e51924b1,
title = "Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients",
abstract = "Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76{\%}) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24{\%}). CK20 expression was associated with reduced overall (HR 2.92, 95{\%} CI 1.04⁻8.16) and disease-specific (HR 4.62, 95{\%} CI 1.31⁻16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95{\%} CI 1.06⁻4.36) and recurrence-free (HR 3.08, 95{\%} CI 1.44⁻6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.",
author = "Marco Rastrelli and Beatrice Ferrazzi and Francesco Cavallin and {Chiarion Sileni}, Vanna and Jacopo Pigozzo and Alessio Fabozzi and Saveria Tropea and Antonella Vecchiato and Alessandra Costa and Alessandro Parisi and Rossi, {Carlo Riccardo} and {Del Fiore}, Paolo and Mauro Alaibac",
year = "2018",
month = "9",
day = "24",
doi = "10.3390/cancers10100350",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Prognostic Factors in Merkel Cell Carcinoma

T2 - A Retrospective Single-Center Study in 90 Patients

AU - Rastrelli, Marco

AU - Ferrazzi, Beatrice

AU - Cavallin, Francesco

AU - Chiarion Sileni, Vanna

AU - Pigozzo, Jacopo

AU - Fabozzi, Alessio

AU - Tropea, Saveria

AU - Vecchiato, Antonella

AU - Costa, Alessandra

AU - Parisi, Alessandro

AU - Rossi, Carlo Riccardo

AU - Del Fiore, Paolo

AU - Alaibac, Mauro

PY - 2018/9/24

Y1 - 2018/9/24

N2 - Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04⁻8.16) and disease-specific (HR 4.62, 95% CI 1.31⁻16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06⁻4.36) and recurrence-free (HR 3.08, 95% CI 1.44⁻6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.

AB - Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04⁻8.16) and disease-specific (HR 4.62, 95% CI 1.31⁻16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06⁻4.36) and recurrence-free (HR 3.08, 95% CI 1.44⁻6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.

U2 - 10.3390/cancers10100350

DO - 10.3390/cancers10100350

M3 - Article

C2 - 30249978

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

ER -